Favorable response to dasatinib for extramedullary relapse after allogenic transplantation in a patient with <i>NUP214-ABL1</i>-positive B-cell precursor acute lymphoblastic leukemia

DOI
  • Okuhiro Yuki
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Okada Keiko
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Tanimura Kazuki
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Hira Kota
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Nakano Yoshiko
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Yamasaki Kai
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Nitani Chika
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Fujisaki Hiroyuki
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital
  • Fukushima Hiroko
    Department of Pathology, Osaka City General Hospital
  • Inoue Takeshi
    Department of Pathology, Osaka City General Hospital
  • Hara Junichi
    Department of Pediatric Hematology and Oncology, Osaka City General Hospital

Bibliographic Information

Other Title
  • 同種移植後の髄外再発に対し，ダサチニブが著効した<i>NUP214-ABL1</i>融合遺伝子陽性B前駆細胞性急性リンパ性白血病の1例

Search this article

Description

<p>Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by a gene expression signature similar to that of Ph-positive ALL (Ph+ALL). The outcome for patients with Ph-like ALL may be improved by treatment with tyrosine kinase inhibitors; however, it is difficult to identify Ph-like ALL by conventional cytogenetic and molecular analyses. Here, we present the case of a female adolescent with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) having a NUP214-ABL1 fusion, which was identified from the results of array comparative genomic hybridization (aCGH). She experienced extramedullary relapse after allogeneic HSCT, but achieved complete remission after receiving dasatinib. This suggests that tyrosine kinase inhibitors might be effective for Ph-like ALL with a NUP214-ABL1 fusion.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top